OncoMatch/Clinical Trials/NCT05621668
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Is NCT05621668 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cyclophosphamide and attIL2-T cells for soft tissue sarcoma.
Treatment: Cyclophosphamide · attIL2-T cells — To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Osteosarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1 K/uL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100 K/mm3
Kidney function
Serum creatinine ≤ 2 mg/dL OR creatinine clearance > 50 mL/min
Liver function
AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤ 1.5 x ULN
Cardiac function
LVEF >50%
Absolute neutrophil count (ANC) ≥ 1 K/uL, Hemoglobin ≥ 9 g/dL, Platelets ≥100 K/mm3; Serum creatinine ≤ 2 mg/dL OR creatinine clearance > 50 mL/min; AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤ 1.5 x ULN; Cardiac function: LVEF >50%; Pulmonary function: Oxygen saturation >92% on room air, Total lung capacity >70% of predicted, DLCO >60% of predicted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify